SYNTHETECH - NZYM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SYNTHETECH - NZYM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (323)	4/8/2000 9:21:00 PM
From: Dan Gibbs	Read Replies (2) of 372

I was looking through the Bristol-Myers annual report today and was intrigued by their top new drug called Vanlev (omapatrilat). It is a new type of antihypertensive that has been submitted for fast track FDA approval. The accompanying graphic of its structure looks a lot like a small peptide so I did a little research and it is a mercaptoacyl-based dipeptide mimetic. It has two actions: 1) it functions like lisinopril and captopril as an angiotensin-converting enzyme inhibitor and 2) it inhibits neutral endopeptidase. This second action increases circulating levels of certain vasoactive peptides that promote vasodilation, lowering blood pressure. I haven't asked Sreeni if NZYM is supplying PBLs for this drug (he wouldn't tell me anyway), but I suspect that the synthesis of this drug would use the type of peptide building blocks that NZYM makes. The BMY report says they are planning a launch in 2000 (pending approval) and if NZYM is a supplier, this could be a huge source of revenue. Lots of speculation, but, hey, what else do we have to talk about.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next